Shenyang Sinqi Pharmaceutical

Shenyang Sinqi Pharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, production, and commercialization of ophthalmic medications. The company maintains a dominant position in the domestic eye care market, offering a comprehensive portfolio that includes eye drops, gels, and ointments for conditions such as myopia, dry eye, and glaucoma. Sinqi gained significant international attention for its 0.01% Atropine Sulfate eye drops, which became the first product of its kind to receive NMPA approval for slowing the progression of myopia in children. Headquartered in Shenyang, the company operates integrated R&D and manufacturing facilities and is listed on the Shenzhen Stock Exchange. Sinqi continues to expand its pipeline with both innovative new drugs and high-quality generic ophthalmic products to address the growing demand for vision health in China.